Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advancing healthcare through personalized medicine / / Priya Hays
| Advancing healthcare through personalized medicine / / Priya Hays |
| Autore | Hays Priya <1968-> |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (755 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Precision medicine
Medicina personalitzada |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-80100-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface to the Second Edition -- Acknowledgments -- Contents -- 1: "Introduction: Biomedical Innovation and Policy in the Twenty-First Century" -- Liquid Biopsy -- Challenges and Incentives for Implementation -- Components of the Book -- References -- 2: "The Rise of Genomics and Personalized Medicine" -- Human Genome Project, Sequencing, and Genomic Medicine -- New Innovative Studies in NGS -- Sanger Sequencing and Comparison with NGS -- Single-Cell RNA Sequencing -- Single-Cell Epigenetic Analysis -- Application of Single-Cell Analysis in Precision Cancer Therapy -- Genomic Medicine -- Genomic Sequencing for Assessment of Disease -- Potential Challenges of Genomic Medicine -- ENCODE: Mapping the Functional Genome -- Pharmacogenetics: Pharmacogenomics -- Thiopurine-Methyltransferase (TPMT) -- CYP2D6 -- CYP2C9 -- UDP-Glucoronyltransferase -- HIV and Abacavir -- Targeted Panel Sequencing -- Genomics-Enabled Medicine for Cancer Prognosis -- The Emergence of Personalized Medicine -- Biomarker Discovery -- Tumor Mutational Burden (TMB) as a Biomarker -- Germline Considerations -- Conclusion -- References -- 3: "Patient Narratives: Personalized Medicine in the Field" -- The Population of 1 Trial: The Story of Milasen -- The Narratives of Personalized Medicine -- Social Media's Avenues for Personalized Medicine -- Social Media for Patient Engagement -- Role of Twitter in Identifying Barriers to Care Among Patients with Metastatic Breast Cancer [6] -- The Narrative of Xin Zheng: A Lung Cancer Success Story -- References -- 4: Alliances: Knowledge Infrastructures, and the Digitization of Precision Health -- Precision Medicine: Its Potential Development and Implementation -- Implications of Precision Medicine for Patient Care and Disease Treatment -- Monitoring the Personal Genome -- Macroeconomic Considerations of Precision Medicine.
Global Alliance for Genomics and Health -- Updates to Global Alliance for Genomics and Health: GA4GH 2020 (Figs. 4.7, 4.8, 4.9, and 4.10) -- Systems Thinking and -Omics Technologies -- Data Portals and Data Analysis -- Bridging the Gap for Translational Genomic Research -- Database Efforts -- Genomics and Artificial Intelligence -- Deep Learning Methods in Precision Medicine -- Digital Precision Health: The History of Machine Learning and the Power of Big Data for Clinical Medicine -- Digital Pathology -- Conclusion -- References -- 5: "Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics" -- An Immunotherapy Case Report -- A Target Therapy Case Report -- The Basis for Targeted Therapies: Acquired Mutations and Biomarkers in Cancers -- Oncogenesis -- Implications of Tumor Heterogeneity -- Enrichment and Adaptive Strategies -- Molecular Abnormalities in Solid Tumors -- Germline Molecular Testing for Hereditary Cancer Risk -- Cell Cycle Checkpoints -- Understanding Clinical Trials in the Era of Precision Oncology: Data, Biomarkers, and Diagnostic Testing -- Analysis -- Action -- N of 1 Trial -- Tumor Subtypes -- Breast Cancer -- Incidence and Mortality -- Inherited Breast Cancer -- Targeted Therapy Options in Breast Cancer Care -- Tyrosine Kinase Inhibitor: Tucatinib -- HER2+ /HER2-Positive Breast Cancer -- Triple-Negative Breast Cancer (TNBC) and Metastatic Breast Cancer (mBC) -- Biomarker Predicting Response to PARP Inhibitors -- "Study Supports Using MRD as a Stratification Variable for Patients with TNBC" -- "Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer" -- Olaparib -- Talazoparib -- Immunotherapy and Immunotherapy Combinations -- Newer Generation Targeted Therapy Agents -- Abemaciclib -- Other Combination Agents -- Recent Immunotherapies. Tecentriq -- Pembrolizumab -- Avelumab -- Liquid Biopsy in Breast Cancer: A Systematic Review -- Current Breast Cancer Diagnosis Standards -- Oncotype DX -- MammaPrint -- PAM50 (Prosigna) -- Genomic Grade Index (GGI) (Ipsogen) -- Veridex Rotterdam Signature 76 Genes -- Ventana HER2 Dual ISH DNA Probe Cocktail Assay for Detection of HER2 -- RSClin TOOL: 21-Gene Recurrence Score (RS) -- HER2DX -- Signatera MRD Test -- Findings for Protein-Truncating and Missense Variants -- "Study Suggests 86-SNV Be Incorporated in Breast Cancer Risk Prediction Models" -- Conclusion -- Colorectal Cancer -- Incidence and Mortality -- Colorectal Cancer Classification Systems -- Molecular Pathology and Diagnosis of Colorectal Cancer -- "Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile" -- Inherited CRC Syndrome -- Hereditary Nonpolyposis Colorectal Carcinoma (Lynch Syndrome) -- Familial Adenomatous Polyposis -- De Novo Colorectal Cancer -- BRAF V600E -- Additional CRC Biomarkers and Mutations -- Targeted and Immunotherapies -- Bevacizumab -- Cetuximab -- Panitumumab -- Ramucirumab -- Ziv-aflibercept -- ASPECCT Trial [76] -- Immunotherapies for CRC: A Recent Development -- Immunotherapy for the Nonimmunogenic Tumors -- Liquid Biopsy -- Conclusion -- Melanoma -- Incidence and Mortality -- Targeted Therapies -- BRAF-V600E Inhibitors -- Immunotherapies for Melanoma -- Multicenter Double-Blind Phase III IMMUNED Trial -- The Phase III Double-Blind EORTC 1325/KEYNOTE-054 Trial (continued) -- Immunotherapies in Combination with Targeted Agents -- Adoptive Cell Therapy for Metastatic Melanoma -- Liquid Biopsy -- "Pretreatment ctDNA May Help Predict Outcomes With First-Line-but Not Second-Line-Immunotherapy for Patients With Melanoma" -- Management of Brain Metastases from cuM -- Conclusion -- Lung Cancer -- Incidence and Mortality. Targeted Therapies -- "Pyrotinib for Pretreated Patients with HER2-Mutated Advanced NSCLC" -- Erlotinib -- Gefitinib -- Afatinib -- Capmatinib -- Dacomitinib -- Summary of Erlotinib, Gefitinib, and Afatinib -- Sotorasib -- Ceritinib -- Alectinib -- Brigatinib -- Lorlatinib -- Selpercatinib -- Pralsetinib -- Newer Targeted Therapy Agents -- Osimertinib -- Tepotinib -- Use of Liquid Biopsy in the Trial -- Poziotinib -- Ramucirumab/Erlotinib -- Mobocertinib -- Capmatinib -- Brigatinib -- Adagrasib -- Immunotherapies -- Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC -- KEYNOTE-024 -- KEYNOTE-042 -- KEYNOTE-189 -- KEYNOTE-407 -- KEYNOTE Trials Adverse Events -- IMpower Trials -- IMpower 110 -- IMpower 130 -- IMpower 131 -- IMpower 150 -- Durvalumab -- Comparative Analysis of Pembrolizumab or Nivolumab in NSCLC -- The ORIENT-11 Trial Showed Sintilimab Plus Chemotherapy Improves PFS in Advanced NSCLC -- The PD-L1 Status Dilemma -- CheckMate Trials -- CheckMate 227 -- CheckMate 9LA -- Molecular Diagnosis -- Molecular Genotyping in NSCLC -- Role of Plasma-Based Molecular Genotyping in NSCLC -- Liquid Biopsy -- Case Studies of Liquid Biopsy in Lung Cancer -- Case Study 1 -- Case Study 2 -- Case Study 3 -- Case Studies 4 and 5 -- Case Study 6 -- Conclusion -- Prostate Cancer -- Incidence and Mortality -- Genomic Medicine and Sequencing -- Newer Generation Targeted Therapies -- Prostate-Specific Membrane Antigen -- PARP Inhibitors -- "Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer" -- Rucaparib -- Non-metastatic Prostate Cancer -- PROSPER -- SPARTAN -- ARAMIS -- Summary of PROSPER, SPARTAN, and ARAMIS -- Immunotherapies -- Molecular Diagnosis -- Liquid Biopsy -- Genetic Screening -- Which Men Should Be Evaluated for Prostate Cancer?. Key Genomic Differences Identified in the Prostate Cancer of African-American Men -- "Series of Studies Identify Genetic Risk Factors for Prostate Cancer" -- "17q22 Loss Associated With Survival in Enzalutamide-Resistant mCRPC" -- Racial Differences in Genomic Profiles of Primary and Metastatic Prostate Cancer -- "Study Finds Differences in BRCA1/2 Male Pathogenic Variant Carriers" -- Diagnostic Tests -- 4 k Score -- Prostate Health Index (PHI) -- Prostate Cancer Antigen 3 Assay (PCA3) -- SelectMDx -- ExoDx Prostate Intelliscore (EPI) -- ConfirmMDx -- Prognostic Tests -- Decipher (GC) -- Post-operative Radiation Therapy Outcomes Score -- Promark -- Prolaris -- OncotypeDx Genomic Prostate Score (GPS) -- Precision Imaging -- Conclusion -- Central Nervous System Tumors -- Incidence and Mortality -- Molecular Classification of Glioblastoma -- Diffuse Astrocytic and Oligodendroglial Tumors -- IDH-Mutated Astrocytomas -- Biomarkers and Targeted Therapies -- Tumor Immunology -- Subset of Glioblastoma Tumors Identified as Immunotherapy Candidate -- Meningiomas -- Hemangioblastomas -- Conclusion -- Hematological Malignancies -- Incidence and Mortality -- Hematologic Oncology Highlights 2019-2020 Almanac -- Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia -- Study Finds Asciminib Safer and More Effective than TKI Bosutinib in Chronic Phase CML -- "Effects of Stopping Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia: -- Focus on Molecular Response and Patient-Reported Outcomes" -- "First-Line Dasatinib Plus Blinatumomab for Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" -- Clinical Trials Investigating the Efficacy and Safety of the Novel CART Therapies UCART 19 and UCART22 in R/R B-Cell ALL -- "Chemotherapy Plus Blinatumomab for Philadelphia Chromosome-Negative B-Cell ALL". "FDA Grants Fast Track Designation to Allogeneic CAR T-Cell Therapy for Advanced ALL". |
| Record Nr. | UNINA-9910502660103321 |
Hays Priya <1968->
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hot and cold theory : the path towards personalized medicine / / Maryam Yavari, editor
| Hot and cold theory : the path towards personalized medicine / / Maryam Yavari, editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (182 pages) |
| Disciplina | 615.5 |
| Collana | Advances in experimental medicine and biology |
| Soggetto topico |
Alternative medicine
Biology - Research Precision medicine Medicine - Research Medicina personalitzada |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030809836
9783030809829 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910520087103321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Organoid Technology for Disease Modelling and Personalized Treatment / / edited by Badrul Hisham Yahaya
| Organoid Technology for Disease Modelling and Personalized Treatment / / edited by Badrul Hisham Yahaya |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2022 |
| Descrizione fisica | 1 online resource (209 pages) |
| Disciplina | 610.28 |
| Collana | Stem Cell Biology and Regenerative Medicine |
| Soggetto topico |
Stem cells
Regenerative medicine Diseases - Animal models Medicine - Research Biology - Research Stem Cell Biology Regenerative Medicine and Tissue Engineering Disease Models Translational Research Medicina regenerativa Cèl·lules mare Teràpia cel·lular Medicina personalitzada Òrgans (Anatomia) |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030930561
9783030930554 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. The hope and the hype in organoid technology in regenerative medicine (Badrul Hisham Yahaya) -- Chapter 2. Pluripotent stem cell derived and adult-tissue-derived organoid (Tiago G. Fernandes) -- Chapter 3. Generation of human organoid for 3D stem cell culture Hans Clevers -- Chapter 4. Organogenesis in a dish: Organ developmental study using organoid technology (Kursad Tuksen) -- Chapter 5. Disease modelling using patient-derived organoid (Narisorn Kitiyanant) -- Chapter 6. Tumor organoid as a model to study cancer microenvironment (Ahmad Faried) -- Chapter 7. Gene-editing in organoid to improve understanding of human disease (Yinming Liang) -- Chapter 8. Organoid culture as a good model to study lung development (Mitsuru Morimoto) -- Chapter 9. Organoid as good model for respiratory diseases (Badrul Hisham Yahaya).-Chapter 10. In vitro 3D model on reproductive system (Ruttachuk Rungsiwiwut) -- Chapter 11. Modelling of neuronal organoid: The way forward and challenges (Juntang Lin) -- Chapter 12. Generation of cardiac organoid in early heart organogenesis (Tan Jun Jie) -- Chapter 13. Neural Crest-Derived Stem Cells in organoid development for neurodegenerative disease modelling (Darius Widera) -- Chapter 14. Organoid for drug discovery and personalized treatment (Toshio Takahashi) -- Chapter 15. Ethical concern on patient-derived organoid (Phuc Van Pham). |
| Record Nr. | UNINA-9910544848903321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Personalized specialty care : value-based healthcare frontrunners from the Netherlands / / Nico van Weert, Jan Hazelzet, editors
| Personalized specialty care : value-based healthcare frontrunners from the Netherlands / / Nico van Weert, Jan Hazelzet, editors |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (VIII, 172 p. 29 illus., 28 illus. in color.) |
| Disciplina | 615.7 |
| Soggetto topico |
Precision medicine
Medicina personalitzada |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-63746-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Personalized care as value-driven care -- Evidence Based Medicine and personalized care -- The IBD coach for person-oriented care -- Onco-geriatric MDO is based on treatment goals of older oncology patients -- I repair: EHealth application in the interest of the patient, healthcare professional and the BV. The Netherlands. a school example of value-driven care! -- Metabolic network for customized prevention and treatment -- Personal attention for the patient in Zorgpad Pituitary tumor -- Value-driven care for chronic kidney damage -- From process improvement aimed at quality and safety to a change process with care providers and patients to achieve personalized care: Radboudumc Basis op Orde -- Care monitor supports outcome-oriented care for patients with head and neck cancer -- Cleft lip and palate -- Turner -- Breast Cancer in the Region with Dashboard / The State of Patient-Centered Breast Cancer Care: an Academic Center's Experience and Perspective -- Pregnancy and childbirth care -- Better experiences of rheumatism patients through value-driven patient journey -- Organizational bed for person-centered care -- Interprofessional learning and working -- With regional funding towards transparent and personalized care. . |
| Record Nr. | UNINA-9910484582503321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics / / edited by Erika Ruiz-Garcia, Horacio Astudillo-de la Vega
| Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics / / edited by Erika Ruiz-Garcia, Horacio Astudillo-de la Vega |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (X, 171 p. 19 illus. in color.) |
| Disciplina | 611.01816 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Molecular biology
Cancer research Pharmaceutical technology Immunology Biomedical engineering Genetics Molecular Medicine Cancer Research Pharmaceutical Sciences/Technology Biomedical Engineering/Biotechnology Genetics and Genomics Medicina personalitzada Càncer |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-24100-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Pharmaco-Geno-Proteo-Metabolomics and Translational Research in Cancer -- Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in Cancer -- Pharmaco-epigenomics: on the road of translation medicine -- Design and Implementing Pharmacogenomics Study in Cancer -- Onco-omics approaches and applications in Clinical Trials for Cancer patients -- Issues and Ethical Considerations in Pharmaco-oncogenomics -- Pharma-oncogenomics in the era of personal genomics: a quick guide to online resources and tools -- Inmuno-Oncology in the era of Personalized Medicine -- CAR T Cell and Personalized Medicine -- Oncobiome at the forefront of a novel molecular mechanism to understand the Microbiome and Cancer -- Nutrition, Cancer and Personalized Medicine -- Index. |
| Record Nr. | UNINA-9910373913203321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
